Prostate cancer is the second leading cause of cancer-related death in men. The present study was carried out to investigate the radiation response of serum cytokines and oxidative markers to find out if these novel biomarkers have significant applications regarding radiation outcome in prostate cancer patients. Significant elevations of prostatic specific antigen (PSA), asymmetric dimethyl arg...

PURPOSE Prostate cancer is among the most common non-cutaneous neoplasms affecting renal transplant recipients (RTRs). Available treatments including radical prostatectomy and external beam radiotherapy carry a risk of damage to the transplanted kidney, ureters, or bladder. We assessed the safety and efficacy of Iodine-125 ((125)I) prostate seed brachytherapy as an alternative to surgery and ra...

OBJECTIVE Radiotherapy for prostate cancer does not explicitly take into account daily variation in the position of the rectum. It is important to accurately assess accumulated dose (DA) to the rectum in order to understand the relationship between dose and toxicity. The primary objective of this work was to quantify systematic (Σ) and random (σ) variation in the position of the rectum during a...

OBJECTIVE To investigate whether patient-reported quality of life after high-dose external beam intensitymodulated radiotherapy for prostate cancer can be improved by decreasing planning target volume margins while using real-time tumor tracking. METHODS Study patients underwent radiotherapy with nominal 3-mm margins and electromagnetic real-time tracking. Morbidity was assessed before and at t...

AIM OF THE STUDY The evaluation of quality of life during image-guided radiotherapy (IGRT) in patients with prostate cancer. MATERIALS AND METHODS The study consisted of 180 prostate cancer patients treated with radical radiotherapy (IGRT). The patients were irradiated using conformal or dynamic techniques with 2 Gy fractionation doses to a total dose of 76 Gy. Patients in the high-risk group...

PURPOSE This study was performed to evaluate the results and prognostic factors associated with radiotherapy for a detectable serum prostate specific antigen level after radical prostatectomy. MATERIALS AND METHODS From July 1987 through July 2003, 368 patients received radiotherapy for a detectable prostate specific antigen level (biochemical relapse) as the sole evidence of recurrence after...

PURPOSE To evaluate the outcomes of high-risk prostate cancer patients treated with biologically effective dose (BED) ≥ 220 Gy of high-dose radiotherapy, using low-dose-rate (LDR) brachytherapy in combination with external beam radiotherapy (EBRT) and short-term androgen deprivation therapy (ADT). MATERIAL AND METHODS From 2005 to 2013, a total of 143 patients with high-risk prostate cancer w...

INTRODUCTION Early localisation of disease recurrence after definitive treatment of prostate cancer is vital to determine suitability for salvage treatment. Our aim was to further investigate the relationship between prostate specific antigen (PSA) level and detection of suspected cancer recurrence using 68  Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy (RP)...

Background: Prostate cancer is the second most frequent in men after lung cancer, it accounts for 3.8% of all deaths caused by worldwide. This study aimed at determining prevalence, grades and management prostate among male patients admitted with Oncology Department Bugando Medical Centre. Methodology: was a hospital-based retrospective cross-section that retrieved data from 384 medical files w...

To quantify the incremental costs and outcomes of using long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. The cost of radiotherapy for prostate cancer has been calculated using an activity-costing model. The total cost of administering adjuvant hormonal therapy for 3 years is based on local pharmacy charges plus typical physician billing fees and add...